Since 1975, CFRI has supported CF research at well-established nonprofit medical facilities through the funding of grant awards. Our investment in new ideas has enabled researchers to bring new perspectives to the study of this disease. Those involved in varied disciplines of research are encouraged to submit grants to advance the current understanding of cystic fibrosis.
CFRI seeks to fund projects that are original, probing
and /or pioneering a new approach to a therapy or cure for cystic fibrosis. CFRI funds CF research through the Elizabeth Nash Memorial Fellowship (ENMF) and the New Horizons Research (NH) program, as well as through the Special Circumstance Grant, that allows CFRI to respond to important and timely projects which fall outside the guidelines of the ENMF and NH programs.
The Elizabeth Nash Memorial Fellowship (ENMF) provides funding to Post Doctoral Fellows engaged in CF-related research at local institutions and encourages collaborative research and communication between the institutions and Principal Investigators (PI’s). The Fellowship aims to support new and promising research in critical areas at well recognized laboratories.
The New Horizons (NH) program supports research of the highest scientific quality that also has the greatest relevance to finding improved treatments or a cure for cystic fibrosis. The NH awards provide seed funding for promising new lines of basic and clinical CF research which show prospects of future funding by other sources, such as the National Institutes of Health (NIH).
All programs are governed by the Research Advisory Committee (RAC), a volunteer group of researchers, clinical physicians, adults with CF, and parents/family members of those with CF. Staff and Board of Directors representatives are involved as well.
All research proposals are submitted to and reviewed by the RAC, and undergo a rigorous peer review process. Results are ranked by the RAC based on reviewers’ comments. Recommendations for funding are presented to the Board of Directors for evaluation. CFRI’s annual research funding budget is approved by the voting membership of the agency.
For additional information, please contact Scott Wakefield, Programs and Operations Associate, at email@example.com.
Moving Research Forward
As researchers answer questions on the molecular and biochemical mechanisms of CF, more questions follow as the complexity of this disease is encountered. This is why the dedication of CFRI in supporting research is so important.
CFRI’s programs—the Elizabeth Nash Memorial Fellowship and the New Horizons Campaign—have funded research such as Pseudomonas and its interaction with the epithelium, alternate signaling pathways that induce chloride channel function, the role of calcium-activated chloride channels in the lung, antioxidants and the CF lung, mucous gland regulation and secretion, and CF lung microbial populations and their role in susceptibility to infection—all critical issues for CF patients.
The grants we receive are high quality, peer reviewed, and thoughtfully evaluated by Research Advisory Committee members before final funding recommendations are made. My only regret as chair of the RAC is that we don’t have enough funds to support all the proposals we receive.
CFRI Research Advisory Committee Chair